English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background  c‐ros oncogene 1 (  ROS1 )  rearrangement presents one of the newest molecular targets in non‐small cell lung cancer ( NSCLC ).   ROS1   rearrangement is predominantly found in adenocarcinoma cases and is exclusive to other oncogenes, such as epidermal growth factor receptor (  EGFR ) ,  K irsten rat sarcoma viral oncogene homolog (  KRAS ) , and anaplastic lymphoma kinase (  ALK ) . The aim of this study was to investigate the clinicopathological characteristics and outcomes of   ROS1 ‐ rearranged patients with lung adenocarcinoma without   EGFR   and   KRAS   mutations and   ALK   rearrangements.    Methods  Wild‐type   EGFR  /  KRAS  /  ALK   patients with lung adenocarcinoma were selected from  B eijing Chest Hospital. Specimens were conducted in tissue microarrays.   ROS1   rearrangement was screened using fluorescence in situ hybridization.    Results  Our study included 127 patients with lung adenocarcinoma without   EGFR   and   KRAS   mutations and   ALK   rearrangements.   ROS1   rearrangement was detected in five (3.9%) of the 127 patients. Compared with   ROS1  ‐negative patients, the positive rate of   ROS1   in female patients was significantly higher than in male patients (9.8% vs. 0.0%,  P  = 0.009). There were no differences in age, smoking status, stage or histological subtype between   ROS1  ‐positive and   ROS1  ‐negative patients. No significant difference in survival was detected between the   ROS1  ‐positive and   ROS1  ‐negative patients.    Conclusions    ROS1   rearrangement is a rare subset of lung adenocarcinoma. In 127 patients with lung adenocarcinoma, 3.9% of   ROS1  ‐positive patients with wild‐type   EGFR  /  KRAS  /  ALK   were found.

thoracic cancer

Clinicopathological characteristics and outcomes of   ROS1  ‐rearranged patients with lung adenocarcinoma without   EGFR  ,   KRAS   mutations and   ALK   rearrangements